|Mr. Michele Garufi||Co-Founder, Chairman and Chief Exec. Officer||512.19k||N/A||63|
|Dr. Elizabeth Marie Robinson||Co-Founder and Pres of the Nicox Research Institute Srl||N/A||N/A||61|
|Mrs. Sandrine Gestin||Fin. Director||N/A||N/A||50|
|Dr. Michael V.W. Bergamini Ph.D.||Chief Scientific Officer and Exec. VP||N/A||N/A||70|
|Mrs. Emmanuelle Pierry||Sr. Director of Legal Affairs||N/A||N/A||N/A|
Nicox S.A., an ophthalmic company, researches, develops, and markets therapies that target various ophthalmic conditions in France and internationally. The companys product pipeline includes VyzultaTM, an intra-ocular pressure-lowering treatment; and NCX 470, a nitric oxide (NO)-donating candidate to treat glaucoma, as well as stand-alone NO donors for specific applications in ophthalmic diseases. It also provides ZERVIATE, an eye drop formulation of cetirizine for allergic conjunctivitis; AC-120, an eye drop that targets morning eyelid swelling; NCX 4240, a Carragelose eye drop for the treatment of for viral conjunctivitis; and NCX 4251, a patented suspension of fluticasone propionate nanocrystals to treat blepharitis. The company has collaborations with Bausch + Lomb, Astra Zeneca, Merck, and Pfizer. Nicox S.A. was founded in 1996 and is headquartered in Valbonne, France.
Nicox SA’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.